Lung cancer
Conditions
Interventions
Observation group:None
Sponsors
Shanghai changhai hosipatal
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age: >=18 years old; 2. Patients with tumors treated with anlotinib (including patients with acinar soft tissue sarcoma, clear cell sarcoma and other advanced soft tissue sarcomas that have progressed or relapsed; Patients with clinically symptomatic or definite disease progression, unresectable locally advanced or metastatic medullary thyroid cancer; Patients with advanced, locally advanced, or metastatic radioiodine-refractory differentiated thyroid cancer); 3. Complete pre-medication laboratory examination related indicators (blood routine, liver enzyme related indicators, etc.); This criterion is used in patients included in the assessment of adverse reactions; Note: If it is a efficacy-related study, it is necessary to additionally meet the requirements of patients with lung cancer with clear pathological and imaging diagnosis, and patients with locally advanced or metastatic lung cancer who have progressed or relapsed after receiving at least 2 types of systemic chemotherapy, including NSCLC and SCLC.
Exclusion criteria
Exclusion criteria: 1. Refusal to sign informed consent; 2. Unable to evaluate ADR and efficacy-related data; 3. Inability to assess medication adherence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SNPs;complete remission;partial remission;stable disease;progressive disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| progress free survival;overall survival; | — |
Countries
China
Contacts
Public ContactWang Zhuo
Shanghai Changhai Hospital
Outcome results
None listed